Market capitalization | $18.00m |
Enterprise Value | $16.58m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 55.27 |
P/S ratio (TTM) P/S ratio | 60.00 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $300.00k |
EBIT (operating result TTM) EBIT | $-27.24m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Geovax Labs Inc forecast:
4 Analysts have issued a Geovax Labs Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.30 0.30 |
-
|
|
Gross Profit | 0.22 0.22 |
414%
414%
|
|
EBITDA | -27 -27 |
38%
38%
|
EBIT (Operating Income) EBIT | -27 -27 |
38%
38%
|
Net Profit | -27 -27 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
Head office | United States |
CEO | David Dodd |
Employees | 17 |
Founded | 1988 |
Website | www.geovax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.